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Abstract
Follicle-stimulating hormone (FSH) is produced in the pituitary and is essential for 
reproduction.  It  specifically  binds  to  a  membrane  receptor  (FSHR)  expressed  in 
somatic  cells  of  the  gonads.  The FSH/FSHR system presents  many peculiarities 
compared to classical G protein-coupled receptors (GPCRs). FSH is a large naturally 
heterogeneous heterodimeric  glycoprotein.  The  FSHR is  characterized by  a  very 
large NH2-terminal extracellular domain, which binds the FSH and participates to the 
activation/inactivation switch of the receptor. Once activated, the FSHR couples to 
Gs  and,  in  some  instances,  to  other  G subunits.  G  protein-coupled  receptor 
kinases  and  -arrestins  are  also  recruited  to  the  FSHR  and  account  for  its 
desensitization, the control of its trafficking and its intracellular signalling. Of note, the 
FSHR internalization and recycling are very fast and involve very early endosomes 
instead of early endosomes. All the transduction mechanisms triggered upon FSH 
stimulation lead to the activation of a complex signalling network that controls gene 
expression by acting at multiple levels. The integration of these mechanisms leads to  
context-adapted responses from the target gonadal cells, but also indirectly affects 
the fate  of  germ cells.  Depending of  the physiological/developmental  stage,  FSH 
elicits proliferation, differentiation or apoptosis in order to maintain the homeostasis of 
the reproductive system. Pharmacological tools targeting FSHR recently came to the 
fore  and  open  promising  prospects  both  for  basic  research  and  therapeutic 
applications.  This  paper  provides  an  updated  review  of  the  most  salient  aspects  and 
peculiarities of FSHR biology and pharmacology.
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1. Introduction.
Follicle-stimulating hormone (FSH) plays a crucial  role in the control  of  male and female 
reproduction. FSH is a heterodimeric glycoprotein consisting of an  subunit, common with 
the other glycoprotein hormones [i.e.: luteinizing hormone (LH), chorionic gonadotropin (CG) 
and thyroid-stimulating hormone (TSH)], which is non-covalently associated with a specific 
FSH subunit  (Pierce  and  Parsons,  1981,  Ryan  et  al.,  1987).  FSH  is  synthesized  and 
secreted by the pituitary. FSH binds to and activates a plasma membrane receptor (FSHR) 
that belongs to the rhodopsin family of the G protein-coupled receptor (GPCR) superfamily. 
The  FSHR  displays  a  high  degree  of  tissue  specificity,  being  expressed  in  Sertoli  and 
granulosa cells located in the male and female gonads respectively  (Simoni et al.,  1997)
(Figure 1). As the other glycoprotein hormone receptors, the FSHR is characterized by a 
large NH2-terminal extracellular domain (ECD), where FSH binds specifically. 
FSH is  required for  normal  growth and maturation  of  ovarian follicles  in  women and for 
normal spermatogenesis in men (Themmen and Huhtaniemi, 2000). Female mice with FSH
or FSHR gene knockout are infertile because of an incomplete follicle development, whereas 
male  display  oligozoospermia  and  subfertility  (Kumar  et  al.,  1997,  Dierich  et  al.,  1998). 
Consistently, women expressing non-functional variants of the FSHR are infertile while men 
are oligozoospermic, yet fertile (Aittomäki et al., 1995).
Because of its glycosylation,  FSH is naturally heterogeneous and must  be expressed by 
mammalian cells (i.e.:  pituitary or CHO cells) to be fully active  in vivo.  Because of these 
characteristics, only native forms of FSH, either purified from urine or recombinant, are being 
used in reproductive medicine, no other pharmacological agents being currently available in 
clinic  (Lunenfeld, 2004, Macklon et al., 2006). Some women treated with FSH develop an 
ovarian  hyperstimulation  syndrome  (OHSS),  which,  in  its  severe  forms,  can  be  life-
threatening (Vloeberghs et al., 2009). Therefore, pharmacological agents that would induce 
ovulation without the risk of provoking OHSS would represent a major improvement. It is also 
well established that, in women, the responsiveness to FSH treatment is heterogeneous and 
that the dose and sometimes the source of FSH, have to be empirically adjusted for each 
patient (Loutradis et al., 2003, Loutradis et al., 2004). A larger panel of FSHR agonists with 
varying  pharmacological  profiles  could  certainly  help  improving  the  overall  efficiency  of 
medically-assisted  procreation.  On  the  other  hand,  FSHR  blockers  could  potentially 
represent a novel non-steroidal approach for contraception (Naz et al., 2005). 
In order to meet these challenges, it is important to gain a better understanding of FSHR 
biology and the bottlenecks that make the targeting of this receptor particularly difficult. 
2. FSH and FSH-R in pathologies.
FSH serum levels vary physiologically during the menstrual cycle in women. Nevertheless, 
abnormal  pituitary  FSH  secretion  can  occur  in  different  pathologies  such  as  Premature 
Ovarian Insufficiency (POI) and Polycystic Ovarian Syndrome (PCOS). POI is a dysfunction 
of the ovary occurring in about 1% of female population (under 40 years old)(Goswami and 
Conway,  2005).  Patients  carrying  POI  are  infertile  due  to  anovulation,  amenorrhea  and 
reduced secretion  of  oestrogens  (Kalantaridou  et  al.,  1998).  One key  parameter  for  the 
diagnosis  is  based  on elevated FSH serum levels  (>  40 IU/l)  found  in  non-menopausal 
women  (Conway,  2000).  The  higher  FSH  levels  are  caused  by  diminished  oestrogens 
production  that  abolishes  the  negative  feedback  at  the  pituitary  gland  resulting  in 
hypersecretion of FSH and LH (hypergonadotrophic hypogonadism). Interestingly, a woman 
with a mutation in the β-subunit of FSH presented infertility and amenorrhea. This mutation 
resulted in a truncated β-subunit, which was unable to bind the α-subunit and to activate the 
receptor (Matthews et al., 1993). These authors hypothesized that mutation at the FSH level 
could represent a possible cause of POI but a parallel study was unable to find any mutation 
in the hormone in a group of 18 women affected by POI  (Layman et al.,  1993). Another 
worldwide women–affecting disease (5-10%) (Franks, 2013), in which FSH and its receptor 
seem to play a role, is PCOS. PCOS is the commonest cause of infertility due to anovulation 
in  women  (Ben-Shlomo  and  Younis,  2014) and,  according  to  Rotterdam  criteria,  the 
diagnosis is based on the presence of oligomenorrhoea, hyperandrogenism and ovary with 
diffuse  cysts  (Rotterdam,  2004).  The  causes  are  not  fully  understood  but  many  studies 
demonstrate environmental  and genetic  (Ben-Shlomo and Younis,  2014) contributions  as 
well as a specific evolutionary cause (Casarini and Brigante, 2014, Casarini et al., 2016d). 
Since low levels  of  serum FSH are encountered in  PCOS, an open debate regards the 
possible correlation of FSH levels as a cause for the anovulation found in PCOS. In this 
scenario,  the  interpretation  of  anovulation  denotes  the  incapacity  of  FSH  to  select  the 
dominant follicles and lead them to maturation, consequently, there is an accumulation of 
immature follicles in the ovary (Franks et al., 2000). This possible implication of FSH hypo-
responsiveness is in disagreement with in vitro experiments on granulosa cells derived from 
anovulatory women suffering of PCOS, who showed a hypersensitivity to FSH stimulation in 
terms of oestradiol production. This apparent paradox could be clarified by considering the 
abnormal endocrine environment, together with the heterogeneity of the follicles (different 
follicle sizes have different responses to gonadotropins) (Willis et al., 1998) found in ovaries 
of  women  affected  in  PCOS-derived  anovulation  (Franks  et  al.,  2008).  Genetically,  the 
involvement of two common FSHR polymorphisms (Thr307Ala and Asn680Ser) has been 
considered in the pathogenesis of PCOS but no stronger and definitive correlation has been 
demonstrated to date (Chen et al., 2014). In male, FSH/FSHR contribution to infertility is not 
fully elucidated due to a lack of knowledge about the role of FSH in spermatogenesis. In the 
clinical practice, administration of FSH is used to treat idiopathic male infertility (IMI) (Ulloa-
Aguirre and Lira-Albarrán, 2016) but this treatment remains controversial since disrupting 
mutations in the FSH/FSHR has no effect on fertility in human and mouse  (Kaprara and 
Huhtaniemi,  2017).  Finally,  a  pathogenic  function  has  been  recently  assigned  to  the 
FSH/FSHR system in tumours. Some studies show the expression of FSHR in different types 
of tumours including ovarian, prostate and endothelial cancers, but the data are debated and 
based  on  small  cohort  of  patients  (Papadimitriou  et  al.,  2016).  Further  investigations  is 
necessary to clarify the role of FSH/FSHR in malignancies.
3. FSH role in assisted reproduction technologies.
Assisted Reproduction Techniques (ART) are defined as “all treatments or procedures that 
include the in vitro handling of both human oocytes and sperm or embryos for the purpose of 
establishing a pregnancy” (Zegers-Hochschild et al., 2009). The procedures involved in ART 
include In  Vitro Fertilization  (IVF),  Gamete  Intrafalloppian  Transfer  (GIFT)  and 
Intracytoplasmic Sperm Injection (ICSI). Although a universal ART protocol does not exist, 
the main steps are common to each technique (Casarini et al., 2016a). Briefly, the starting 
point is the suppression of the natural menstrual cycle and pituitary gland function, which is 
followed by the induction of ovulation through the injection of urinary or recombinant FSH 
preparations in a procedure called Controlled Ovarian Stimulation (COS). After the follicle 
has reached a proper size, maturation of the oocyte is obtained by administration of drugs, a 
phase known as ovulation triggering. The following step is the selection and collection of the 
best  oocytes that  will  ultimately  undergo fertilization by using one of  the aforementioned 
techniques. Finally, the fertilized oocyte is re-implanted in the uterus and the luteal phase is 
pharmacologically supported  (Farquhar et  al.,  2015).  The ovarian stimulation is  the main 
responsible for the success or failure of ART. The purpose is to obtain as many as possible 
growing follicles, in order to allow oocytes to mature and consequently to be retrieved and 
fertilized. This goal is achieved by maintaining FSH blood serum levels above the threshold, 
simply subjecting women to daily FSH injections (Baird, 1987). The choice between urinary 
or recombinant FSH is completely arbitrary since different studies have demonstrated the 
equivalence of the two preparations in terms of efficacy and safety (Daya and Gunby, 2006). 
Since a standard protocol for ovarian stimulation is not available, clinicians adjust FSH dose 
administration in a patient-personalized mode, taking into account the different degrees of 
ovarian  responsiveness  to  FSH.  In  this  context,  women  undergoing  COS  protocol  for 
assisted reproduction are generally divided in normal, poor and high responders. The range 
of urinary or recombinant FSH administration goes from 150 IU for high responders up to 375 
IU for poor responders whereas a medium concentration (200 – 300 IU) is used for normal 
responders (Alviggi et al., 2012). It has been suggested that poor responders might benefit of 
the  addition  of  luteinizing  hormone  (LH)  in  the  FSH  preparation  but  more  solid 
demonstrations are needed (Hill et al., 2012). The CONSORT study attempted to create an 
algorithm to calculate  the personalized dose of  recombinant  FSH in  ART. The algorithm 
considers different parameters (basal FSH serum levels, body mass index, age, etc.) and 
proposes a mathematical model for FSH dose calculation that can be used as a starting point 
for  personalized FSH administration  in  ART protocols  (Olivennes et  al.,  2009).  A severe 
complication  due  to  gonadotropin  administration  in  ART is  the  Ovarian  Hyperstimulation 
Syndrome (OHSS). The incidence is variable but it  can be as high as 20%  (Smith et al., 
2015) in women treated for ART. OHSS are classified as mild, moderate or severe and result 
in exaggerated ovarian response to gonadotropins. The causes are still unknown but many 
studies attempted to correlate OHSS with different  parameters (antral  follicle  count,  anti-
Müllerian hormone levels,  oestradiol  concentration,  etc.)  in  order  to  find risk factors and 
consequently  delineate  preventive  strategies  (Nastri  et  al.,  2015).  Mutations  at  the  FSH 
receptor were also considered as a risk factor for OHSS occurrence but the mutations were 
found in a spontaneous form of OHSS (Dieterich et al., 2010). Infact, FSH receptor mutations 
are generally  very rare in  ART-induced OHSS.  On the contrary, FSHR single nucleotide 
polymorphisms  (SNPs)  Ser680Asn  correlates  with  a  high  severity  of  OHSS  in  women 
carrying this SNP  (Rizk,  2009). Finally, genetics of  FSH and FSHR, including mutations, 
SNPs  or  combination  of  them  resulting  in  different  haplotypes  might  affect  COS  and 
consequently assisted reproduction outcome, or might be used as genetic marker of ovarian 
response, but further supporting evidences is needed (Riccetti et al., 2017).
4. FSHR structure and function.
The human FSHR,  together  with  LHR and  TSHR,  belongs  to  the glycoprotein  hormone 
receptors subfamily of class A GPCRs. It is encoded by a unique gene constituted of 10 
exons and located on chromosome 2p21-p16 (Rousseau-Merck et al., 1993). After releasing 
of a signal peptide of 17 amino acids, the mature membrane FSHR protein contains 678 
amino acids. Its molecular weight varies between 82 and 89 kDa depending on the rate of N-
glycosylation (Davis et al., 1995). Several splice variants have been reported in human, [for a 
review (Ulloa-Aguirre and Zarinan, 2016)], some of them coding for altered isoforms with no 
or reduced signalling potential (Gerasimova et al., 2010, Karakaya et al., 2014, Zhou et al., 
2013).
The FSHR structure consists in an extracellular hydrophilic domain (ECD) composed of a 
long N-terminal part and three loops. This ECD connects to a hydrophobic region comprising 
seven transmembrane domains (TMDs) and intracellular hydrophilic regions composed of 
three intracellular loops and the C-terminal part (Figure 2)  (Jiang et al., 2012, Jiang et al., 
2014a,  Fan and Hendrickson,  2005,  Ulloa-Aguirre and Zarinan,  2016).  The ECD can be 
functionally divided into two subdomains, the hormone binding domain (HBD) consisting of 
ten consecutive leucine-rich repeats domains (LRR) and the hinge region located between 
the HBD and the first TMD. The hinge region contains two additional LRR, followed by a 
hairpin loop and an alpha helix flanked on both sides by two cysteine box motifs that are able 
to  form  cysteine  bonds  between  themselves.  The  hinge  ends  with  a  highly  conserved 
decapeptide (FNPCEDIMGY), located close to the first TMD reported to be necessary for 
receptor activation  (Bruser et al.,  2016). A currently proposed model predicts that ligand-
induced activation of FSHR operates following a two-step process. The first step corresponds 
to the binding of FSH on the HBD. The crystal structure of the hormone in complex with the 
HBD has been solved  (Fan and Hendrickson, 2005). The winding structure determined by 
the  ten  LRR requires  that  the  HBD takes  the  form  of  a  curved  tube.  The  dimensional 
difference between the inner and outer surface of this tubular structure is responsible for the 
curvature  (Jiang et al., 2012, Jiang et al., 2014a). Analysis of the FSH-HBD crystal shows 
that FSH binds into the concave face of the curved HBD domain where the beta sheets of  
the LRR motifs are located. The long axis of FSH is perpendicular to the HBD tube and 
aligned  with  the  LLR  beta  sheets.  Therefore,  FSH  associates  with  the  HBD  like  a  « 
handclasp » (Jiang et al., 1995). The buried interface has a high charge density. Contact with 
hormone is mainly ensured by ten residues, charged for the most part (L55, E76, D81, R101, 
K104, Y124, D150, D153, K179, I222). Some of them participate to the FSHR specificity for 
FSH (L55, E76, R101, K179, I222) and discrimination against LH/CG (L55, K179) and TSH 
(E76, R101) binding [reviewed in (Jiang et al., 2014a)]. The carbohydrates do not take part in 
the binding interface (Fan and Hendrickson, 2005). Nevertheless, two of the three possible 
N-glycosylation sites of the ECD can actually be glycosylated (N174 and N276) and at least 
one of the two is required for binding FSH activity (Davis et al., 1995).
The binding of FSH on the HBD enables the second step of the ligand-induced receptor 
activation consisting of a conformation change in the hinge region. The crystal structure of 
the entire FSHR ECD bound to FSH has highlighted the role of the hinge region for FSHR 
activation (Jiang et al., 2012, Jiang et al., 2014a). FSH binds more tightly the HBD when the 
hinge  region  is  present  than  in  its  absence.  Even  if  the  entire  ECD  shows  a  greater 
accessible buried interface than the HBD alone, leading to a more rigid FSH conformation, 
the main reason for the gain in affinity comes from the presence of a sulfated tyrosine (Y335) 
in the hairpin loop of the hinge that constitutes a second interaction site between FSH and its 
receptor. FSH binding to the inner surface of the HBD induces the formation of a sulfated-
tyrosine pocket between the FSH  and  chains, absent in the free form of the hormone. 
The  sulfated  tyrosine-binding  pocket  interacts  with  the  sulfated-Y335  and  neighbouring 
residues of FSHR and hence provokes the tilting of the hairpin loop and the rotation of the -
helix  of  the  hinge  region.  This  causes  a  conformational  change  of  the  TMDs,  then  the 
extracellular  loops may interact  with the charged residues in  the hairpin loop and finally 
stabilize the active state of the receptor. It  has also been proposed that the hinge region 
could act as a tethered inverse agonist keeping the RFSH in its inactive conformation. The 
FSH  binding  on  the  HDB could  alleviate  this  inhibitory  effect  by  changing  the  receptor 
conformation. Consistent with this view, the removal of the hinge region, with the exception of 
the conserved decapeptide, leads to increased constitutive activation level of FSHR and loss 
of its ability to respond to FSH (Agrawal and Dighe, 2009). The inactive state driven by the 
hinge region and maintained by an unoccupied HDB, coupled with a discriminating binding 
interface for LH/CG and TSH, allows the FSHR to remain inactive in the absence of FSH, 
even when high concentrations of others glycoproteins are circulating. Constitutively active 
mutants of FSHR are rare, probably because they induce severe pathologies (Ulloa-Aguirre 
et al.,  2014). The mutations responsible for three of them target two different TMDs and 
induce conformational changes of FSHR that decrease its binding specificity. Consequently, 
these mutant forms of FSHR can be activated by high concentrations of CG or TSH. 
Like others glycoprotein hormone receptors, FSHR was observed as a monomer/oligomer. It 
has been shown, using FRET microscopy, that FSHR can form oligomers in endoplasmic 
reticulum early during biosynthesis (Thomas et al., 2007). In this study, oligomers of FSHR 
were observed at the cell surface and FSH had little effect on FSHR oligomerization. Later 
on, it was shown that FSHR could heterodimerize with LHR (Mazurkiewicz et al., 2015). Fan 
and Hendrickson showed that the dimerization of the ectodomain occurs only through a weak 
interaction which could be mediated via residue Y110, suggesting that a stronger interaction 
could be carried out by another domain of the receptor, notably by the alpha-helices of the 
TMDs, as suggested by Ulloa-Aguirre and Zarinan  (Ulloa-Aguirre and Zarinan, 2016, Fan 
and Hendrickson, 2005). A model for a trimeric FSH receptor has also been proposed by 
Jiang et al.  (Jiang et al., 2012, Jiang et al., 2014a, Jiang et al., 2014b). According to this 
model,  only  one fully  glycosylated FSH molecule  would  be able  to bind to a trimer  and 
therefore just one of the three receptors would be activated. 
5. FSHR mutations.
Although rare in the population, activating and inactivating mutations of FSHR have been 
reported in both genders (Riccetti et al., 2017, Desai et al., 2013, Ulloa-Aguirre et al., 2014). 
Both  types  of  mutations  can  cause  alteration  of  reproductive  function,  even  though  the 
phenotype is often more severe for woman fertility. In most  cases, inactivating mutations 
provoke primary or secondary amenorrhea whereas the activating ones generally lead to an 
OHSS. Some studies described the impact of mutations on both the functional properties of 
the mutated receptor and the resulting phenotype and contributed to extend the knowledge 
of the structure/function relationship of FSHR.
Inactive mutations in the ECD mostly impair cell surface expression/trafficking of the receptor 
while  FSH  binding  of  the  hormone  is  often  reduced.  Accordingly,  signal  transduction  is 
negatively  impacted,  leading  to  a  greater  or  lesser  decrease  of  the  production  of  FSH-
induced cAMP. However, Aittomaki et al. showed that the A189V mutation, located in the 
HDB, provokes the decrease of the cAMP responsiveness induced by FSH, but has no effect 
on the affinity of the FSHR for the hormone (Aittomäki et al., 1995). Some residues in the 
HDB may play a different role than those merely involved in binding affinity for the ligand. 
Similarly,  FSHR  carrying  the  P348R  mutation  in  the  hinge  region  does  not  bind  FSH, 
suggesting that residues outside of the HDB participate to FSH binding (Allen et al., 2003). 
In TMD2, two different mutations lead to a decrease by half of the production of FSH-induced 
cAMP. Bramble et al., have reported that the D408Y mutation impairs the trafficking of the 
receptor, the decrease of both the expression at the cell surface and the signal transduction 
being  proportional  (Bramble  et  al.,  2016).  For  the  A419T  mutation,  the  cell  surface 
expression was not evaluated, but the ligand binding capacities of the mutated and wild type 
receptors were similar (Doherty et al., 2002).
Two mutations located in TMD6 present different impact on signal transduction. The A575V 
mutation leads to an increase of cell surface expression but a slight decrease of the binding 
affinity, and therefore does not show any difference in FSH-induced cAMP compared to wild 
type  (Desai  et  al.,  2015).  Kuechler  et  al.  showed  that  the  P587H  mutation  completely 
abolished cAMP production  upon FSH stimulation  (Kuechler  et  al.,  2010).  This  mutation 
could  induce  a  distortion  of  a  proline-dependent  helix-kink  at  this  position,  which  is 
particularly important for signal transduction in class A GPCRs. The P519T mutation located 
in extracellular loop 2 (ECL2) decreases FSH binding and cell surface expression, impairing 
cAMP response in vitro. This mutated receptor could remain trapped intracellularly due to the 
alteration of the cell surface targeting. The decrease of ligand affinity suggests that ECL2 is 
involved in the binding mechanism, possibly via direct interaction with the ECD (Meduri et al., 
2003). In ECL3, mutation of the 601 residue impairs the signal transduction without reducing 
the binding capacity although two diverging reports were published. Ryu et al., reported that 
mutation L601A improves FSH binding while Touraine et al. showed that this mutation does 
not affect FSH binding (Ryu et al., 1998, Touraine et al., 1999). The cellular trafficking of the 
L601V mutant is not affected and does not explain the dramatic decrease of FSH-induced 
cAMP  response.  Similarly,  R573C  mutation  also  located  in  the  ICL3,  decreases  signal 
transduction without reducing hormone binding capacity and cell surface expression (Beau et 
al., 1998). Hugon-Rodin et al. first described a mutation in the intracellular C-terminal tail of 
RFSH in the case of a non-pregnant women with OHSS  (Hugon-Rodin et al.,  2017). The 
R634H mutation  is  located  in  the  highly  conserved  BXXBB motif  (B  represents  a  basic 
residue and X any non-basic residue), which is needed for cell surface trafficking and plasma 
membrane  expression  (Ulloa-Aguirre  et  al.,  2007,  Duvernay  et  al.,  2004).  This  mutant 
displays  decreased  cell  surface  expression  that  leads  to  a  lowered  cAMP production  in 
response  to  FSH.  However,  as  this  mutation  was  identified  in  an  a  OHSS  patient,  an 
activating mutation was expected. Moreover, this mutant does not exhibit any constitutive 
activity. Further investigation will be necessary to solve this conundrum and find a causal link 
between the mutation and the clinical data.
Activating mutations of FSHR have been identified in most structural/functional domains of 
the FSHR and have been shown to lead to OHSS by different molecular mechanisms. Some 
mutated receptors display increased constitutive activity and promiscuous binding to hCG 
and TSH compared to wild type FSHR: T449N and T449A in TMD3 (Banerjee et al., 2017, 
Montanelli et al., 2004), I545T in ID3 (Montanelli et al., 2004, Smits et al., 2003) and I545T in 
TMD5 (De Leener et al., 2008). De Leneer et al suggested that the gain of sensitivity of the 
mutants to hCG (or TSH) could be due to the lowering of an intramolecular barrier aiming at  
preventing activation rather than to an increase in binding affinity  (De Leener et al., 2008). 
These mutated receptors respond to the increasing hCG levels occuring during pregnancy 
and TSH levels in case of hypothyroidism. Activating mutations displaying other properties 
have also been reported. De Leneer et al. described the S128T mutation located in the ECD 
(De Leener et al.,  2008). This mutant displays an increased sensibility for hCG due to a 
greater affinity but not for TSH, and does not present any constitutive activity. In this case, 
the mutation could modify the interaction between residues from hCG and HDB. Mutants 
devoid of constitutive activity or increased responsiveness to hCG and TSH have also been 
described. Desai et al. reported the V514A mutation located in the ECL2, which induces an 
increase of  cell  surface expression and binding affinity along with reduced internalization 
(Desai et al., 2015). Interestingly, this mutant displays better FSH responsiveness for cAMP 
production. Even though maximal efficacy does not seem to change, the improved signal 
transduction at low FSH concentration could explain the advent of OHSS in this patient.
6. FSHR signalling through G proteins.
Unlike many GPCRs, in the absence of ligand, FSHR displays little to no constitutive activity 
(Ulloa-Aguirre  et  al.,  2014).  This  functional  characteristic  correlates  with  the  increased 
stability of the transmembrane domains in the inactive state compared to other glycoprotein 
hormone  receptors  (Zhang  et  al.,  2007,  Ulloa-Aguirre  et  al.,  2014).  Upon  FSH binding, 
conformational changes in the receptor lead to the transduction of extracellular signal, hence 
the  activation  of  several  intracellular  signalling  pathways  dependent  of  heterotrimeric  G 
proteins.  In  all  animal  species  and  in  physiological  conditions,  the  primary  transduction 
mechanism described for  FSHR involves the heterotrimeric Gs proteins  (Abou-Issa and 
Reichert, 1979, Ayoub et al., 2015, Musnier et al., 2009, Dattatreyamurty et al., 1987, Remy 
et al.,  1995, Gershengorn and Osman, 2001). The Gs-subunit interacts with intracellular 
loops 2 and 3 of the activated FSHR at the level of the ERW and BBXXB (B: basic residue,  
X:  non-basic  residue)  motifs  respectively  (Jiang  et  al.,  2012,  Ulloa-Aguirre  and  Zarinan, 
2016, Ulloa-Aguirre et al., 2007). Several intracellular events are then observed: 1) exchange 
of Gs-subunit-linked GDP to GTP, 2) dissociation of Gs-subunit-GTP and G subunits, 
and 3) stimulation of  the adenylate cyclase by Gs-subunit-GTP inducing an increase of 
intracellular cAMP levels and its propagation into the cell. The main function of cAMP is to 
activate  protein  kinase  A (PKA)  that  in  turn  phosphorylates  various  substrates  such  as 
transcription  factor  cAMP response  element-binding  protein  (CREB)(Hunzicker-Dunn  and 
Maizels, 2006, Hansson et al., 2000). Intracellular cAMP also leads to the activation of the 
exchange proteins directly activated by cAMP (EPACs) (Kawasaki et al., 1998, Wayne et al., 
2007, de Rooij et al., 1998). It has been reported that the Gs/cAMP/PKA pathway may be 
lost  in  some  FSHR  mutants  derived  from  altered  splice  transcripts  in  exons  10  which 
encodes  the  G  protein  coupling  domains  (Sairam  et  al.,  1996).  Noteworthy,  the  cAMP 
pathways  is  strongly  amplified  downstream  of  FSHR  since  maximal  response  can  be 
reached with only a few percent of FSHR being occupied (Ayoub et al., 2015). In line with 
many other GPCRs, FSHR has demonstrated a certain degree of promiscuity with other G 
proteins rather than being exclusively  coupled to Gs.  Indeed,  it  has been reported that 
FSHR is able to interact with Gi (Gorczynska et al., 1994) and Gq (Quintana et al., 1994). 
FSHR is able to activate pertussis toxin-sensitive Gi  protein in presence of glycosylated 
variants of FSH (Arey et al., 1997, Timossi et al., 2000) and in Sertoli cells at specific stages 
of maturation  (Crepieux et al., 2001) whereas it has been reported to activate Gq protein 
when  FSH  reaches  supra-physiologic  concentrations  (>  200  ng/ml)  (Ito  et  al.,  2003, 
Gloaguen et al., 2011, Conti, 2002).
7. FSHR desensitization, internalization and recycling.
The FSHR is regulated by the canonical desensitization mechanisms known to operate for 
most  GPCR  (Figure  3).  Briefly,  agonist-activated  FSHR  is  rapidly  phosphorylated  on 
serine/threonine residues located on its carboxyl terminus through the action of G protein-
coupled receptor kinases (GRKs), specifically GRKs 2, 3, 5 and 6 (Ayoub et al., 2015, Kara 
et al.,  2006, Lazari et al.,  1999, Marion et al.,  2006, Moore et al.,  2007, Troispoux et al., 
1999,  Ulloa-Aguirre  and  Zarinan,  2016).  Non-visual  arrestins  (-arrestin  1  and  2)  are 
subsequently recruited and overlap with G protein binding sites on the receptor (Ayoub et al., 
2015, Nakamura et al., 1998, Stoffel et al., 1997). Through this interaction, -arrestins -1 and 
-2 prevent the coupling between FSHR and heterotrimeric G proteins by steric hindrance 
(Reiter  et  al.,  2017,  Reiter  and Lefkowitz,  2006,  Thomsen et  al.,  2016).  The  amount  of 
intracellular  cAMP then  decreases  and  the  receptor  becomes  refractory  to  further  FSH 
stimulation  (Marion  et  al.,  2002).  Once  desensitized,  the  FSHR  is  thought  to  follow 
intracellular  routing  and  molecular  events  similar  to  those  that  have  been  largely 
demonstrated  for  other  GPCRs.  In  short,  the  receptor  is  internalized  via the  clathrin-
dependent  endocytic  pathway, resensitized and recycled back at  the plasma membrane. 
Upon binding to the FSHR, -arrestins undergo conformational rearrangements inducing the 
exposition of binding motifs in the C-tail that interact with various elements of the endocytic 
and recycling machinery (Luttrell and Lefkowitz, 2002, Moore et al., 2007, Tian et al., 2014) 
such as clathrin (Goodman et al., 1997, Goodman et al., 1996), clathrin-associated adapter 
complex  AP2  (Laporte  et  al.,  2000,  Laporte  et  al.,  1999),  phosphoinositides  (PIP2, 
phosphatidylinositol 4,5-bisphosphate, IP3, phosphatidylinositol 3,4,5-trisphosphate and IP6, 
inositol hexakisphosphate) (Gaidarov et al., 1999, Toth et al., 2012), dynamin (Zhang et al., 
1996), ADP-ribosylation factors (ARFs) specifically ARF-6 and ARNO its activity modulator 
(ARF nucleotide-binding  site  opener)  (Frank  et  al.,  1998,  Shmuel  et  al.,  2006);  small  G 
proteins  (Rab)  (Moore et  al.,  2007) and  N-ethylmaleimide-sensitive  fusion  protein  amine 
(NSF)  (McDonald  et  al.,  1999).  Before  recycling  to  the plasma membrane,  the  receptor 
localized  in  endosomal  vesicle  must  be  resensitized  (Luttrell  and  Lefkowitz,  2002).  The 
receptor  is  then  dephosphorylated  by  phosphatase  PP2A  recruited  by  -arrestins  and 
dissociated from its  agonist  by an acidic  pH in the vesicle  (Luttrell  and Lefkowitz,  2002, 
Thomsen et al., 2016). FSHR exhibits well the desensitization and internalization properties 
of class A GPCRs. Indeed, the internalization is transient, rapid and maximal between 2 and 
5  min  post-stimulation,  the  receptor  resensitization  is  predominant  compared  to  the 
degradation and the recycling process is fast (half time of about 10 min) (Ayoub et al., 2015, 
Moore et al., 2007, Thomsen et al., 2016, Kara et al., 2006). Unlike Gs-coupling, more than 
90% of FSHR occupancy is required in order to achieve maximal -arrestin recruitment and 
internalization (Ayoub et al., 2015).
Early endosomes (EE) have been considered as the primary site for initial post-endocytic 
sorting of some GPCRs (Sposini and Hanyaloglu, 2017). However, FSHR has recently been 
reported to traffic to very early endosomes (VEE) for its post-endocytic sorting. The VEE is 
an endosomal compartment distinct from the EE, which plays a key role in direct spatial 
control of FSHR but also LHR and 1AR signalling (Jean-Alphonse et al., 2014). The VEE is 
smaller than EE and lacks typical EE markers. However, the adaptor protein containing PH 
domain, PTB domain, and Leucine zipper motif (APPL1) is expressed in VEE subpopulations 
(Jean-Alphonse et al., 2014, Sposini et al., 2017). Interestingly, the divergent sorting of FSHR 
between EE and VEE is mediated by association with the PDZ protein Gi interacting protein 
C  terminus  (GIPC).  Moreover,  the  sustained  ERK activation  profile  elicited  upon  FSHR 
stimulation requires both internalization and targeting to VEE in a GIPC-dependent manner 
(Jean-Alphonse et al., 2014).
8. FSHR signalling through -arrestin.
Beyond their well established role in receptor desensitization, internalization and recycling, -
arrestins  have  progressively  emerged  as  key  players  in  the  control  of  GPCR-mediated 
signals  in  time  and  space  (Figure  3).  Many  GPCRs,  including  FSHR,  have  been 
demonstrated to signal independently of heterotrimeric G protein, through ligand-induced -
arrestin 1 and 2 recruitment  (Reiter et al., 2012, Reiter et al., 2017, Reiter and Lefkowitz, 
2006). Indeed, -arrestins act as multifunctional scaffolds and activators for a large number 
of signalling proteins  (Xiao et al.,  2007, Xiao et al.,  2010, Crepieux et al.,  2017). A well-
documented illustration of the temporal encoding in GPCR-induced signalling pathways that 
-arrestins can exert is the dual mechanism of ERK activation reported for several GPCRs 
including the FSHR. G protein-mediated ERK activation is rapid and transient. In contrast, 
the ERK signal activated via  -arrestins is slower in onset (~5-10 min to reach maximum), 
but protracted (t1/2 > 1 hour) (Ahn et al., 2004, Kara et al., 2006).
Importantly, -arrestin-dependent signalling is a tightly regulated process. Upon FSH binding, 
the FSHR adopts an active conformation and becomes a target for GRK phosphorylation. 
Specifically,  GRK5  and  6  have  been  reported  to  compete  with  GRK2  and  3  for  the 
phosphorylation of different receptors including the FSHR. Indeed, GRK5 and 6 have been 
shown to promote -arrestin-dependent ERK activation whereas GRK2 and GRK3 inhibit the 
same pathway  (Kara et al., 2006, Heitzler et al., 2012, Kim et al., 2005, Ren et al., 2005, 
Shenoy et al., 2006). In line with these results, recent studies have provided direct evidence 
of the phosphorylation bar code for different GPCRs (Busillo et al., 2010, Butcher et al., 2011, 
Lau et al., 2011, Nobles et al., 2011). Collectively, these findings support a model in which 
the  stabilization  of  distinct  receptor  conformations  subsequently  leads  to  specific 
phosphorylation  patterns  involving distinct  GRK subtypes.  This  phosphorylation  bar  code 
could then control the conformation of β-arrestin recruited to the receptor and thereby its 
ability to interact with specific partners. This cascade of molecular events would ultimately 
control receptor fate and the -arrestin-dependent intracellular signalling in a specific manner 
(Reiter et al.,  2012). It  has recently been demonstrated that 5-HT2R, β2AR, CXCR4 and 
FSHR activate the ERK pathway  via a mechanism involving MEK-dependent β-arrestin 2 
phosphorylation at Thr383. Importantly, this agonist-induced phosphorylation of  -arrestin 2 
is  a  necessary  step  for  ERK  recruitment  to  β-arrestin  complex  and  for  ERK  activation 
(Cassier et al., 2017). In addition to ERK, -arrestins have been reported to be required for 
the activation of p70S6K and rpS6 (Trefier et al., 2017, Wehbi et al., 2010b).
In the classical view, G protein signalling originates at the cell surface and is followed by 
rapid -arrestin-mediated quenching of G protein signalling. Recent findings have begun to 
challenge  this  paradigm.  A number  of  GPCRs have  been reported to  elicit  sustained G 
protein signalling, rather than being desensitized after initial agonist stimulation (Calebiro et 
al., 2009, Feinstein et al., 2011, Ferrandon et al., 2009, Irannejad et al., 2013, Mullershausen 
et al., 2009). In line with these data, it has been proposed that, for some GPCRs, a series of 
distinct signalling waves could arise upon activation  (Lohse and Calebiro, 2013): i) a first 
wave triggered at the cell surface upon G-protein coupling and second messenger release; ii) 
a second wave originating from clathrin-coated pits/vesicles where  -arrestin bound to the 
receptor  would  induce  signals  such  as  ERK  activation  and  iii)  a  third  wave  involving 
signalling  via  G proteins  from the endosomal  compartment.  X-ray  crystallography  of  the 
2AR in complex with Gs has revealed that the interaction involves both the N-terminal and 
C-terminal domains of the Gs subunit and the core of the receptor (i.e.: ICL2, TM5, and 
TM6) (Rasmussen et al., 2011). Importantly, a recent study revealed that -arrestins interact 
with two different sites on the receptor; one is the phosphorylated receptor carboxyl terminus 
and a second, within the core of the receptor  (Shukla et al., 2014). Moreover, internalized 
receptor  complexes called “megaplexes”  composed of  a single GPCR,  -arrestin,  and G 
protein  were  recently  discovered  and  their  architecture  and  functionality  were  described 
(Thomsen et al., 2016). Even though the validity of this model is not yet fully established in 
the case of the FSHR, recent works from Hanyaloglu’s group on LHR and FSHR suggest that 
analogous mechanisms could  operate  for  these receptors as well  (Jean-Alphonse et  al., 
2014, Sposini et al., 2017).
9. Modelling of FSHR signalling.
FSH signalling acts at different time scales within the hypothalamic-pituitary-gonadal (HPG) 
axis, encoding and decoding complex signals across several organs and tissues from the 
pituitary cells to the somatic cells in the gonads. Capturing the mechanisms responsible for 
such refined controls has proven very challenging. Over the years, this topic has led to the 
development of numerous mathematical models. 
Fluctuations of FSH circulating levels are tightly regulated with respect to those of LH, GnRH 
and steroids, displaying striking temporal patterns. A large part of mathematical modelling of 
FSH signalling consists in physiologically based pharmacokinetic (PBPK) models based on 
ordinary  differential  equations  (ODE).  The  objective  of  such  models  is  to  represent 
qualitatively  and/or  quantitatively  the  encoding  of  specific  signals  (steady-states  signals, 
sustained oscillations, pulsatility etc.). Early models of FSH dynamics have focused on the 
FSH-oestrogen interactions in  females  (Lamport,  1940,  Thompson et  al.,  1969).  In these 
models, secretion and clearance mechanisms are combined as building blocks, with often 
linear elimination terms and nonlinear (logistic or Hill-type) functions for hormone production, 
incorporating physiological knowledge on hormonal interactions. Qualitative descriptions of 
long time behaviour of hormonal regulation models have been largely developed in the 70s, 
concomitantly with a larger effort of the mathematical physiology community and important 
advance in theoretical understanding of dynamical systems  (Goldbeter, 2002, Keener and 
Sneyd, 1998, Smith, 1995).
The complexity  of  the interactions between FSH, LH, steroids,  and other  key players all 
along the HPG axis has led to more involved mathematical formalisms. Cyclic patterns of 
FSH within the menstrual cycle have particularly received lots of attention. Some authors 
have used algebraic-integro-differential equations (Bogumil et al., 1972, Shack et al., 1971), 
where the tonic and surge releases of FSH and LH are modelled in details, and gonadotropin 
accumulation is governed by steroid-dependent decision function. Later works made use of 
delay  differential  equations,  where  explicit  time  delays  account  for  the  time  needed  for 
hormone  synthesis,  in  order  to  obtain  a  closed  autonomous  system,  more  tractable  to 
stability analysis (bifurcation and existence of stable oscillation patterns are shown)(Clark et 
al.,  2003,  Harris  and  Selgrade,  2014).  In  addition,  inspired  from  works  on  the  male 
reproductive system (Keenan et al., 2000), stochastic differential equations can be used to 
represent finely the GnRH pulse-generator mechanisms, which control in turn FSH synthesis, 
inside  a  detailed  model  of  the  female  menstrual  cycle  (Reinecke  and  Deuflhard,  2007). 
Finally,  comparison  of  dynamical  models  of  circulating  hormone  concentrations  with 
experimental data has to be based on a rigorous statistical framework, adapted to discrete-
time measurements.  Challenges include in  particular  the ability  to  detect  occurrences of 
physiological relevant signal peaks  (Urban et al.,  1991) or to recover secretion rates  (De 
Nicolao et al., 1999). Several methods exist either based on heuristics and synthetic models 
(Vidal et al.,  2012), deconvolution-based methods  (Carlson et al.,  2013), or on ensemble 
models (Keenan and Veldhuis, 2016, Veldhuis et al., 2008). 
As  many  GPCRs,  the  ligand-stimulated  FSHR triggers  G-dependent  and  G-independent 
intertwined signalling pathways, forming a complex signalling network [see (Gloaguen et al., 
2011) for a detailed review] (Figure 4). Briefly, the major G-protein coupling to the FSHR is 
Gαs,  which activates adenylate cyclase,  resulting in  an increase of  intracellular  levels  of 
cAMP. FSHR also couples to Gαi, which on the contrary inhibits adenylate cyclase, reducing 
the levels of cAMP (Crepieux et al., 2001). Finally, FSHR has been shown to couple to Gαq 
(Escamilla-Hernandez et al.,  2008) leading to the increase of IP3 levels.  The increase of 
cAMP resulting from Gαs leads to PKA activation, which in turn activates different activating 
transcription  factors.  cAMP also  activates  EPAC,  which  results  in  activation  of  the  ERK 
cascade. Both PKA and EPAC activate Rap1, which in turn activates Akt (Alam et al., 2004). 
FSHR has also  been shown to activate  different  proteins  in  a  ligand-dependent  and G-
protein-independent manner. Among these partners, APPL1  (Nechamen et al.,  2004) and 
PI3K  (Wayne  et  al.,  2007) have  been  shown  to  activate  Akt.  These  different  functional 
interactions explain how FSHR is able to activate Akt,  through both G-dependent and G-
independent  mechanism,  leading to the fine-tuned regulation  of  transcription.  As  already 
discussed  above,  FSHR,  as  most  GPCRs,  interacts  with  different  GRKs,  which 
phosphorylate  the receptor  at  specific  sites.  GRK-phosphorylated receptors  couple  to  -
arrestin and are internalized. It has been proposed that the FSHR’s fate may differ depending 
on the type of GRK doing the phosphorylation. After internalization, GRK2/3-phosphorylated 
receptors are either degraded or recycled, whereas GRK5/6-phosphorylated receptors may 
be capable of initiating G-independent signalling  (Kara et al., 2006). In particular, GRK5/6-
phosphorylated FSHR complexed with -arrestin would be able to recruit the ERK signalling 
module (Raf,  MEK and ERK),  resulting in  G-independent  ERK activation  (Cassier  et  al., 
2017). The GRK5/6-phosphorylated FSHR complexed with -arrestin is also able to activate 
rpS6, participating in the regulation of protein translation (Wehbi et al., 2010b, Trefier et al., 
2017). The regulation of  protein translation by FSHR also goes through the activation of 
p70S6 kinase by both PKA and Akt/mTOR-dependent mechanisms  (Lécureuil et al., 2005, 
Musnier  et  al.,  2009).  Finally,  through  the  activation  of  Src  and  ADAM17,  the  FSHR 
transactivates EGFR. In turn, FSH-activated EGFR activates different signalling pathways, 
among which ERK activation through Ras and Raf (Wayne et al., 2007), and RB1 inactivation 
through CDK4 (Yang and Roy, 2006). 
In addition to the large number of  interactions within the FSH interaction network, a key 
component  of  the cellular  response comes from the dynamical  aspects  of  the signalling 
network. For instance, different agonists and/or stimulation patterns may activate the same 
pathways  with  a  distinct  temporal  signature,  leading  to  very  different  cellular  responses 
(Kholodenko, 2006, Kholodenko et al.,  2010, Lohse and Hofmann, 2015), or may induce 
dynamical bias in the signalling  (Grundmann and Kostenis, 2017, Klein Herenbrink et al., 
2016, Lane et al., 2017). These complex dynamics motivate the use of dynamical modelling 
techniques to decipher the decoding mechanisms of  the FSHR intra-cellular  signalling.  A 
standard framework to model the dynamics of signalling pathways uses ordinary differential 
equations  (Ayoub et al., 2016a, Kholodenko et al., 2012, Linderman, 2009). A biochemical 
reaction network is  constructed and,  using the law of  mass action,  this reaction network 
leads to an evolution law for the species involved in the network. Iterative refinement of the 
model according to the experimental data is usually needed to answer specific biological 
questions. This process involves several technical steps that have been detailed for the FSH-
induced  β-arrestin  recruitment  dynamics  (Yvinec  et  al.).  These  steps  include  solving 
numerically the ODE model (Higham, 2008), performing numerical optimization to adhere as 
closely as possible to experimental data (Raue et al., 2013) and, using model selection tools, 
to discriminate different functional hypotheses  (Kirk et al., 2013). The FSH-induced cAMP 
pathway has been investigated by  (Clément  et  al.,  2001) with careful  examination  of  its 
steady states and parameter sensibility, and compared to cAMP production in  granulosa 
cells. Dynamic interaction between cAMP and mTOR pathways, leading to the regulation of 
p70S6 kinase, under either FSH or insulin stimulation, was described using experimental 
data from primary rat Sertoli cells (Musnier et al., 2009). This approach allowed to access to 
p70S6 kinase phosphorylation rates and was validated by predictions on pharmacologically 
perturbed conditions. Modelling only the last transcription and translation steps, Quignot and 
Bois explored the dynamic of sex steroid under FSH stimulation, using  in vitro and  in vivo 
experimental  data  on  rat  granulosa  cells  (Quignot  and  Bois,  2013).  Interestingly,  their 
dynamical  model  allows  studying  the  effect  of  endocrine  disrupting  chemicals  on 
steroidogenesis.  We believe  the  FSH-induced  intracellular  modelling  approaches  will  be 
rapidly growing, as more and more biological knowledge shed light on the complexity of its 
interaction network. Many important questions remain and are mathematically challenging. 
For instance, to decipher the impact of the pulsatility of the input signal on the downstream 
intra-cellular  signal  (Bhattacharya  et  al.,  2017,  Clarke  et  al.,  2002),  combination  of 
microfluidic devices and mathematical modelling can be particularly relevant  (Sumit et al., 
2017). To draw a parallel, interesting developments have been done recently on exploring the 
GnRH intra-cellular signalling pathways, and in particular the balance between FSH and LH 
syntheses  and  releases  in  response  to  particular  GnRH  pulse  patterns  (Coss,  2017, 
Stamatiades and Kaiser, 2017). Several interesting modelling approaches have indeed been 
suggested to explain possible pulse-decoding mechanisms of the GnRHR signalling network, 
using  either  deterministic  ODE formalism  (Fletcher  et  al.,  2014,  Pratap  et  al.,  2017) or 
information theoretic approach and stochastic modelling based on single-cell measurements 
(Fletcher et al., 2014, Garner et al., 2016).
Up to now, mathematical models of FSH signalling have been extensively used to represent 
FSH circulating level at  the anatomic scale,  giving interesting qualitative and quantitative 
results  on  the  hormonal  rhythms.  Yet,  these  approaches  intrinsically  lack  mechanistic 
interpretation, as the cellular and intra-cellular scales are not included. Further development 
of FSH intra-cellular modelling, which will benefit from a larger effort in the GPCR modelling 
community, will help to fill the gap between detailed knowledge on molecular interactions and 
global understanding on hormonal dynamics. In turn, this will bring important tools for drug 
screening  and  development  of  innovative  approaches  in  drug  discovery  for  reproductive 
biology.
10. Impact on gene regulation.
FSH  directly  alters  the  pattern  of  genes  expressed  in  somatic  cells  of  the  gonads  by 
regulating  transcriptional  as  well  as  post-transcriptional  events  at  the  level  of  mRNA 
translation and of the miRNA network. The FSH-induced signalling network also indirectly 
promotes  alterations  of  chromatin  condensation  in  germ cells.  Gaining  a  comprehensive 
picture  on  the  FSH-regulated  gene  expression  could  provide  insights  on  how  gonadal 
somatic cells communicate with their neighbouring germ cells. This could unravel the bases 
of  some  spermatogenetic/ovarian  failure  and  potentially  lead  to  the  development  of 
innovative therapies against infertility or of new methods of contraception.
1. Chromatin remodelling
The role of Sertoli cells in providing the physical and nutritional requirements met by germ 
cells to acquire proper size and spermatogenic ability in the adult is known to be regulated, at 
least in part, by FSH. The Sertoli cell/ germ cell dialog is also illustrated by the ability of FSH 
to  modulate  chromatin  remodelling  at  a  crucial  phase  of  spermatogenesis,  that  is, 
spermiation.  This  spermatogenesis  stage  is  characterized  by  the  release  of  elongated 
spermatids  away from Sertoli  cells  following complex  membrane rearrangements,  and is 
particularly sensitive to hormone regulation.  At  that stage, most  histones are dynamically 
replaced by transition proteins prior to the appearance of protamines, which are in charge 
with DNA compaction in haploid cells  (Sassone-Corsi, 2002). Importantly, knock-out of the 
FSHR gene in mice (FORKO mice) causes delayed spermatogenesis (Dierich et al., 1998), 
because of a lack of histone acetylation and ubiquitinylation that precludes their removal from 
chromatin  (Xing  et  al.,  2003).  Similar  observations  have  been  done  in  rats  treated  with 
fluphenazine decanoate that reduces circulating levels of gonadotropins (Gill-Sharma et al., 
2012). Similarly, the FSH signal could alter the compaction of chromatin in granulosa cells of 
the ovarian follicle, leading to phosphorylation of histone H3 in the promoter regions of the c-
fos,  serum/glucocorticoid-inducible  serine/threonine  protein  kinase  (SGK)  and  α-inhibin 
genes, in a PKA-dependent manner (Salvador et al., 2001). 
2. Gene transcription
Over the years, several studies have assessed FSH impact on gene transcription in various 
models and using continuously improving high throughput approaches (Table 1).  Seminal 
transcriptomic analyses have highlighted the effect of FSH on the steady-state expression of 
100 to 300 mRNA, as soon as after 2 hours of in vitro stimulation of prepubertal rat Sertoli 
cells  (McLean et al., 2002). Thereafter, a clearer knowledge on the  in vivo role of FSH on 
gene  expression  has  been  gained  by  passive  immunization  with  neutralizing  anti-FSH 
antidodies in rat (Meachem et al., 2005). Among the hormone-regulated transcripts detected, 
some  well-known  FSH-responsive  genes  had  been  previously  identified  by  in  vitro 
approaches  (e.g.  steroidogenic  acute  regulatory,  androgen-binding  protein,  connexin-43, 
phosphodiesterase 4B, cyclin D1 or insulin-like growth factor binding protein-3). In addition, 
this study also uncovered 48 new targets of FSH regulation, potentially involved in residual 
body phagocytosis (SCARB1), gene expression (Foxa2, NCOR1, SMAD3), remodelling of 
the  seminiferous  epithelium  (Reelin,  MCPT7,  CSPG  4),  or  cell  signalling  (MAPK3K1). 
Concomitant suppression of FSH by neutralizing antibodies and of testosterone action by 
Flutamide led to contrasted regulations of functional clusters according to the stage of the 
seminiferous tubule  (O'Donnell et  al.,  2009). For example, genes of the immune function 
were enriched at stages IX–XIV, which is relevant to secretion of inflammatory mediators 
(Syed et al., 1995) that is enhanced by the phagocytic activity of residual bodies by Sertoli 
cells following spermiation. Similar results were obtained in the hpg mouse model  (Abel et 
al., 2008, Sadate-Ngatchou et al., 2004). These mice lack circulating gonadotropins because 
of  a natural  mutation in  the GnRH gene  (Mason et  al.,  1986),  but  remain responsive to 
exogenously administrated FSH (Singh and Handelsman, 1996). Hence, they provide a nice 
model to analyse the FSH-regulated gene regulation in vivo. Interestingly, these data depict a 
temporally  dynamic  regulation  of  gene  expression  by  FSH,  with  an  early  transcriptional 
response in Sertoli cells and a more delayed indirect response in germ cells  (Abel et al., 
2008).
These initial data have been obtained from DNA microarray experiments, providing a rather 
limited number of differentially expressed genes (DEG). With the advent of next generation 
sequencing (NGS) technologies, the scientific community might gain a more detailed picture 
of  FSH-regulated genes in  physiological  as well  as pathological  conditions,  including the 
identification of splice variants, some of which being known as important mediators of FSH 
biological action (Foulkes et al., 1993). However, RNAseq analysis of the FSH transcriptome 
in zebrafish testis disappointedly failed to increase the number of DEG (Crespo et al., 2016). 
The transcriptomic analyses presented above have provided an atlas of genes regulated by 
FSH signalling in vitro or in vivo, but so far, the transcription factors that could recognize the 
gene regulatory regions are not known. Systemic examination of the FSH-regulated promoter 
regions will certainly highlight the involvement of unexpected transcriptional regulators and 
upstream kinases. For example, the CREB family of transcriptional activators is known to be 
phosphorylated  by  PKA  in  response  to  FSH,  and  its  functional  role  in  preserving 
spermatocyte survival has been demonstrated, following injection of a non-phosphorylable 
version  of  CREB  into  the  seminiferous  tubules  (Scobey  et  al.,  2001).  However,  the 
requirement of CREB in FSH-regulated transcriptional regulations has to be reconsidered 
because not so many FSH-responsive genes include cAMP-responsive element (CRE) in 
their promoter regions (Perlman et al., 2006). For example, a TRANSFAC analysis achieved 
on transcriptomic data to identify FSH-responsive genes in human granulosa cells revealed 
an unexpectedly  high number  of  transcripts  putatively  responsive  to  the GATA family  of 
transcription factors, whereas CREB-dependent genes were less represented in this study 
(Perlman  et  al.,  2006).  Recent  work  has  revealed  that  Foxo1  positively  and  negatively 
controls the expression of most FSH-responsive genes in granulosa cells  (Herndon et al., 
2016).
PKA is considered as the master regulator  of  CREB. However, in FSH-stimulated Sertoli 
cells,  PKA regulates the activity of many other nuclear targets, such as the retinoic acid 
receptor α (Santos and Kim, 2010), a well-known regulator of germ cell development in the 
testis.  More  generally,  FSH-induced  PKA activity  could  be  involved  in  global  chromatin 
remodelling, as illustrated above in granulosa cells. 
In  mammals,  the  essential  role  that  FSH  plays  in  female  fertility  is  illustrated  by  the 
phenotype of FSHβ knockout mice, that exhibit impaired follicular growth, a small uterus and 
are sterile  (Dierich et al., 1998, Kumar et al., 1997). Similar to its role in the seminiferous 
tubule, in the ovary, FSH indirectly drives oocyte throughout folliculogenesis growth via the 
expression of various factors secreted by follicular cells. Hence, transcriptomic analyses of 
granulosa  cells  stimulated  by  FSH help  understanding  the  dialog  between  oocytes  and 
somatic  cells,  and  might  be  useful  approaches  to  optimize  assisted  reproduction 
technologies. In that respect, the transcriptomes induced by β-follitropin (Organon), and a 
glycosylated N-terminal extended FSH variant, FSH1208  (Perlman et al.,  2003) in cycling 
granulosa cells  from normal  patients undergoing IVF (i.e.:  male cause of  infertility)  were 
compared.  Interestingly,  this  comparison  has  revealed  no  difference  between  both 
transcriptomes, suggesting that the FSH glycosylation variant could be used in the clinics 
without apparent modification of the normal gene profile, hence limiting undesirable effects, 
despite its extended half-life. 
Cow  has  long  been  used  as  a  model  to  improve  in  vitro fertilization  methods.  Gene 
expression pattern in the cumulus has been associated with the developmental competence 
of  the  oocyte it  embeds  (Assidi  et  al.,  2008,  Hamel  et  al.,  2010).  In  the mature follicle, 
cumulus cells differentiate from a portion of the granulosa cells and, despite this common 
origin,  cumulus  cells  and granulosa cells  exhibit  distinct  transcriptomic  signatures,  which 
likely underlie different functional properties  (Wigglesworth et al., 2015). These differences 
encompass  genes  involved  in  cumulus  expansion,  steroidogenesis,  cell  metabolism and 
oocyte competence  (Khan et al.,  2015). Recently, the potential role for WNT signalling in 
potentiating FSH action during dominant follicle selection in cow has been highlighted by 
RNAseq (Gupta et al., 2014).
Another interesting model is the coho salmon (Oncorhynchus kisutch) because this species 
only spawns once and then dies. Hence, this is one of a few animal models where follicular 
cells  are  synchronous  and  homogenous,  and  it  can be used to  decipher  the  sequential 
events  that  rhythms folliculogenesis.  Upon  FSH stimulation,  it  appeared  that  the  genes 
expressed during the primary growth were associated with cell proliferation and survival, an 
expression that still markedly increased at the transition to secondary oocyte growth. Then, in 
vitellogenic  follicles,  genes  associated  with  cell  growth  differentiation,  growth  factor 
signalling,  steroidogenesis  and  extracellular  matrix  components  were  highly  expressed. 
Finally, in maturing follicles, the expression of genes associated with ECM function, growth 
factor signalling and steroidogenesis-related genes was increased by FSH (Guzmán et al., 
2014).
3. mRNA translation
FSHR has a very important trophic role in highly specialized post-mitotic cells, in which it 
stimulates  the  production  of  new  constituents.  The  role  of  RFSH  in  the  translational 
regulation of  genes has been proposed for  the first  time in granulosa cells  (Alam et  al., 
2004). During the proliferation of granulosa cells, FSH stimulates the mTOR pathway leading 
to the expression of cyclin D2, whereas testosterone reduces the effects of FSH by blocking 
the  activity  of  PKA.  Inhibition  of  ERK results  in  decreased  phosphorylation  of  an  FSH-
mediated effector of the mTOR, TSC2 (tuberin) and p70S6K pathway  (Alam et al.,  2004, 
Kayampilly and Menon, 2004, Kayampilly and Menon, 2007). FSH stimulates the translation 
of hypoxia-inducible factor-1 (HIF-1) a transcription factor that regulates the expression of 
vascular  endothelial  growth factor  (VEGF),  plasminogen activator  (PLAT),  and insulin-like 
growth factor 2 (IGF-2,) through the PI3K/Akt pathway (Alam et al., 2004). Activation of FSH-
mediated mTOR pathway  is  necessary  for  the  induction  of  some follicular  differentiation 
markers, including the luteinizing hormone receptor (LH), inhibin-α, aromatase P-450, and βII 
subunit  of  PKA.  Akt  phosphorylation  leads  to  the  activation  of  mTOR  which  initiates 
translation by phosphorylating p70S6K on its Thr389 residue  (Alam et al.,  2004). Finally, 
activated p70S6K kinase phosphorylates its substrate rpS6 and forms a translation module. 
In  the  differentiating  Sertoli  cell,  the  cAMP and  PI3K/mTOR pathways  contribute  to  the 
activation of p70S6K by inducing phosphorylation profiles that are distinct from the model 
established by Dennis et al. in the case of insulin (Lécureuil et al., 2005, Dennis et al., 1998)
(Figure 5). Indeed, in the case of insulin-mediated activation, p70S6K is phosphorylated on 
Thr421 Ser424 and Thr389 (Figure) whereas in the case of FSHR-mediated induction, the 
activation profile of p70S6K protein depends on the development stage of Sertoli cells: i) 
during  the  proliferative  phase,  FSH  induces  p70S6K  phosphorylation  on  Thr389  in  a 
PI3K/mTOR-dependent manner and the dephosphorylation on Thr421 and Ser424 in a PKA-
dependent manner (Lécureuil et al., 2005, Musnier et al., 2009); ii) during the differentiation 
phase,  FSH  activates  p70S6K  through  phosphorylation  of  Thr389  in  a  PI3K/mTOR-
independent manner  (Musnier et al., 2009). Indeed, during the differentiation phase, Akt is 
phosphorylated directly by the FSHR signalling and not via transactivation of the insulin-like 
growth factor (IGF) 1 receptor as shown in the mitotic phase (Meroni et al., 2004). FSH could 
use the same transactivation mechanism to trigger the activation of ERK and PI3K, the latter 
modulating the production of lactate and transferrin, which are essential for the maintenance 
of germline metabolism (Meroni et al., 2002, Crepieux et al., 2001, McDonald et al., 2006). A 
recent in vivo study demonstrates that INS-R and IGF-1R may be required for FSH-mediated 
proliferation of Sertoli cells (Pitetti et al., 2013). 
From a functional point of view, these FSH-dependent signalling mechanisms may promote 
changes  in  the  phosphorylation  of  initiation  and  elongation  factors  from the translational 
machinery present at the 5'UTR of mRNAs. In Sertoli cells, FSH stimulates mTOR activity 
that, regulates eIF4G phosphorylation and, likely via p70S6K, the phosphorylation of eIF4B, 
a cofactor of the eIF4A RNA helicase. All these molecular events occurring at the m7GTP 
5’cap of mRNAs induce rapid translation (within a few minutes) of mRNAs such as VEGF 
and c-fos, in the absence of any significant effect on transcription  (Musnier et al.,  2012). 
More recently, the p70S6K/rpS6 translation module has been described to form a constitutive 
molecular  assembly with β-arrestins. The G protein-dependent FSH signalling and the β-
arrestin-dependent signalling cooperatively contribute to the activation of p70S6K in the β-
arrestin/p70S6K/rpS6 complex (Trefier et al., 2017). This complex controls the translation of 
5'TOP  mRNAs,  a  subset  of  mRNAs  that  contain  an  oligopyrimidine  tract  at  their  5′ 
untranslated region. 5’TOP mRNA represent almost 20% of cellular mRNA abundance and 
encode  for  ribosomal  proteins,  poly(A)-binding  protein  and  factors  of  the  translational 
machinery (Hamilton et al., 2006, Iadevaia et al., 2008, Meyuhas, 2000). The translatome of 
the FSHR, that is the complete list of target mRNAs translated under the influence of FSH, is 
not  yet  established.  In  the  future,  such  high  throughput  approaches  should  help  better 
understanding the dynamics and functional consequence of FSH-mediated translation.
4. miRNA network regulation
In the recent  past,  accumulating evidence have pointed to microRNAs (miRNAs)  as key 
players in the control of male reproduction  (Papaioannou et al., 2011, Papaioannou et al., 
2009). This assumption originates from the knock-out of the Dicer gene that is responsible for 
miRNA biogenesis and processing. Hence, cell responsiveness to FSH extends far beyond 
the regulation of mRNA transcription and translation, and it is conceivable that a complex 
microRNA network will respond to the hormone, to regulate the stability, hence dynamics, of 
various component of the FSH signalling network. Consistently, a rat model where FSH and 
testosterone  action  was  suppressed  in  vivo,  was  probed  with  a  miRNA  microarray  at 
spermiation (Nicholls et al., 2011). Four of the miRNAs that came out from this analysis were 
complementary to the PTEN mRNA that localizes in the apical region of the cells, close to 
mature spermatids. The hormonal input would lead to the degradation of these miRNAs, 
hence stabilizing PTEN at  spermiation.  Interestingly, the PTEN protein level  is massively 
enhanced following FSH cell  stimulation  in vitro,  leading Sertoli  cells  to achieve terminal 
differentiation (Dupont et al., 2010). Since FSH enhances PTEN protein level within minutes, 
the mechanisms involved is consistent with rapid hormone-induced degradation of a miRNA. 
miRNA networks might regulate the compartimentalization of FSH signalling components and 
might control the kinetics of these biochemical reactions, as shown with the PTEN mRNA. 
Hence spatial restriction of signalling effectors upon Sertoli cell morphological changes could 
correlate to differentiation. 
In female also, Dicer gene knock-out leads to inefficient ovulation (Gonzalez and Behringer, 
2009, Hong et al., 2008, Lei et al., 2010, Nagaraja et al., 2008). In fact, a wide set of miRNA 
are expressed in granulosa cells, and several of them are responsive to FSH, notably in 
primary, secondary and antral follicles (Sirotkin et al., 2014, Yao et al., 2009, Yao et al., 2010, 
Zhang et al., 2017), and appear to play a key regulatory function during follicular growth. For 
example,  the miR10 family is implied in a pro-apoptotic negative feedback loop of TGFβ 
activity, and its expression is counteracted by FSH (Jiajie et al., 2017). In addition, the FSH 
signal down-regulates miRNA that prevent progesterone secretion (Yao et al., 2010).
11. Impact on proliferation/apoptosis/cell survival.
FSH is an important contributor to the fate of somatic cells of the male and female gonad. 
Respectively in Sertoli  cells and granulosa cells,  the hormone regulates proliferation and 
commitment to differentiation. In addition, in the ovary, FSH protects granulosa cells from 
atresia,  a degenerative process that leads to the selection of a dominant follicle within a 
developing cohort. This is the main difference with the role of FSH in Sertoli cells, where 
apoptosis  is  negligible.  The  other  difference  is  that  each  FSH-dependent 
proliferation/differentiation transition occurs cyclically in the growing follicle, until depletion of 
the ovarian reserve. At each cycle, FSH promotes proliferation of granulosa cells from the 
pre-antral stage and then stimulates the expression of the LH-R. In contrast, in male, this 
transition is not periodical. In rodents, for example, FSH promotes Sertoli cell proliferation 
perinatally  (Griswold et al.,  1975, Griswold et al.,  1977, Meachem et al.,  2005), until  the 
blood-testis barrier forms at puberty. Hence, once mitoses cease, the ultimate size of the 
Sertoli cell population is reached. Then, FSH sustains the secretory activity of Sertoli cells 
that supports spermatogenesis during the whole adult life. Hence, at one point, there is a 
switch in the action of FSH either in male or in female. Understanding the molecular bases 
for this decision-making is an exciting challenge that deserves to be addressed in current 
investigations.
a. Proliferation.
In Sertoli cells, the mitogenic action of FSH is potentiated by several paracrine factors, such 
as GDNF (Hu et al., 1999) or IGF1 (Pitetti et al., 2013) whose production may vary locally. In 
granulosa cells,  TGFβ family  are  co-activators  of  FSH mitogenic  effect  (Miró and Hillier, 
1996). One convincing driver of the proliferation to differentiation switch might rely on the 
expression of a cytokine-like FSHR receptor with a single transmembrane pass, following 
alternative splicing of the FSHR gene (Babu et al., 1999). This receptor is expressed early in 
life and promotes Sertoli cell proliferation upon activation of ERK MAP kinases (Babu et al., 
2000). Then, after the switch, the bona fide 7TMD FSHR would be expressed and stimulate 
the cAMP pathway. So far, this cytokine-like FSHR receptor has been identified in granulosa 
cells only. But strikingly, its action is consistent with the observation that FSH activates ERK 
MAP  kinases  in  the  neonate,  to  enhance  expression  of  the  D1  cyclin  that  promotes 
progression through the G1 phase of the cell cycle. In the follicle, enhanced expression of 
Cyclin D2 (Sicinski et al., 1996) and Cdk4 (Yang and Roy, 2004) have been involved in FSH 
mitogenic  action.  A  non-mutually  exclusive  alternative  to  explain  the  switch  relies  on 
developmental  alteration  of  the  miRNA  network  that  would  affect  the  pattern  of  FSH 
regulated genes, as suggested by increasing data in granulosa cells (Jiajie et al., 2017, Lei et 
al., 2010, León et al., 2013, Sirotkin et al., 2014, Yao et al., 2009, Zhang et al., 2017).
b. Differentiation.
In Sertoli cells, decision-making would occur around 13 days post-partum in rat, while the 
hormone signal  switches to  produce  cAMP-dependent  signalling  (Crepieux et  al.,  2001). 
Several  paracrine/  endocrine  signals  antagonize  the  mitogenic  signal  elicited  by  FSH in 
Sertoli  cells  (Gallay et al.,  2014), the most extensively described being thyroid hormones 
(Fumel et al.,  2012,  Holsberger et al.,  2005, Quignodon et al.,  2007, Van Haaster et al.,  
1992).  The  nurturer  role  of  Sertoli  cells  is  nicely  illustrated  by  their  ability  to  stimulate 
carbohydrate metabolism. More precisely, they convert most of their glucose to lactate, that 
germ  cells  use  as  primary  source  of  energy.  This  function  is  stimulated  by  FSH  that 
accelerates glucose transport and lactate dehydrogenase expression (Galardo et al., 2008). 
In the follicle, the FSH-dependent expression of the LHR predominates in the second half of 
the follicular phase, to drive the follicle to the pre-ovulatory, steroidogenic phenotype. Hence, 
the  LHR can be considered  as  the most  prominent  granulosa cell  differentiation  marker 
induced by FSH. The steroidogenic action of  LH is itself  potentialized by FSH in human 
granulosa cells (Casarini et al., 2016c). The mitogenic effect of FSH is counteracted by cyclin 
inhibitors such as p27kip1 (Robker and Richards, 1998) and by Foxo1 that represses Cyclin 
D2 expression. 
c. Apoptosis and survival.
One major function of  FSH is  to counteract  pro-apoptotic signals  in the dominant  follicle 
(Chun  et  al.,  1996).  The  molecular  mechanisms involved  include  the  repression  of  pro-
apoptotic signals such as Bim, whose expression is regulated by Foxo-1 in a PI3 kinase-
dependent manner (Shen et al., 2014, Wang et al., 2012). Conversely, FSH also favors the 
activation of  anti-apoptotic  signals  such as the XIAP family  regulated by NF-�B in a PI3 
kinase-dependent  but  IKK-independent  manner  (Li  et  al.,  1998,  Wang  et  al.,  2002).  β-
arrestins might mediate the protective role of FSH, as shown recently in a granulosa cell like 
(Casarini et al., 2016b).
12.Biased signalling.
It is now well established that GPCRs adopt multiple inactive and active conformations that 
are connected to distinct transduction mechanisms. The notion of signalling bias is coming 
from this complexity. Indeed, a given ligand or receptor mutation can modify the stabilized 
conformation  of  the  receptor-ligand  complex,  as  compared  to  the  wild-type  receptor-
reference-ligand complex  (Galandrin et al., 2007, Granier et al., 2007, Kahsai et al., 2011, 
Kenakin, 2005, Kobilka, 2011, Nygaard et al., 2013, Reiter et al., 2012, Violin and Lefkowitz, 
2007, Wacker et al., 2013, Yao et al., 2006, Zürn et al., 2009). Practically, this conceptual 
framework  delineates  three  levels  of  possible  bias.  First,  ligand  bias  that  leads  to  an 
imbalance  between  the  signalling  pathways  activated  when  compared  to  the  reference 
agonist. Such ligands, by stabilizing a subset of the receptor conformations, potentially lead 
to drugs that are associated with fewer side effects (Whalen et al., 2011). Second, bias can 
occur  in  mutated  receptors  in  which  the  different  pathways  normally  triggered  may  be 
imbalanced  or  impaired  compared  to  the  wild-type  receptor.  Third,  bias  that  are  not 
dependent on the receptor or the ligand but are associated with modifications of the cellular 
context.  This  phenomenon,  also  known  as  «  conditional  efficacy  »,  is  associated  with 
differential expression levels of receptor interacting partners or of molecules downstream in 
the signalling pathways, such as receptor activity-modifying proteins (RAMPs), in different 
cell types (Christopoulos et al., 2003, Kenakin, 2002). Contrary to the two other types of bias, 
conditional efficacy is revealed only when comparing a GPCR in different cellular contexts 
(Landomiel et al., 2014, Ulloa-Aguirre et al., 2011).
a. Ligand bias
i) Orthosteric and allosteric modulators
Over the years, different classes of small molecules capable of binding to and modulating 
FSHR have been reported  (Arey, 2008, Palmer et al.,  2005). In most instances, whether 
these compounds lead to balanced or biased effects compared to FSH alone has not been 
determined yet.  Some of  the described small  molecule agonists  active at  the FSHR are 
interacting with the transmembrane domains, thus exhibiting an allosteric mode of  action 
(Arey, 2008, Arey et al., 2008, Guo et al., 2004, Guo T, 2004, Palmer et al., 2005, Yanofsky et 
al., 2006). Three negative allosteric modulators (NAMs) have been reported. The first NAM 
described  was  ADX61623,  which,  while  increasing  the  affinity  of  FSH  binding,  blocked 
FSHR-mediated  cAMP  and  progesterone  but  not  oestradiol  production  in  rat  granulosa 
primary  cells.  In  vivo,  ADX61623  did  not  affect  FSH-induced  preovulatory  follicle 
development (Dias et al., 2011). Two other NAMs, ADX68692 and ADX68693, with structural 
similarities to ADX61623, were subsequently studied and exhibited biased NAM activities on 
FSHR in rat granulosa primary cells  (Dias et al., 2014, Ayoub et al., 2016b). Indeed, while 
ADX68692  blocked  FSHR-promoted  cAMP,  progesterone  and  oestradiol  production, 
ADX68693 inhibited cAMP and progesterone with the same efficacy as ADX68692 but did 
not block oestradiol production. Interestingly, it was found that ADX68692 but not ADX68693 
decreased the number of oocytes recovered fPalmerrom the ampullae  (Dias et al., 2014). 
Van  Koppen  et  al.  described  a  positive  allosteric  modulator  (PAM):  Org  214444-0  (Van 
Koppen et al., 2013). This PAM showed nanomolar FSHR agonistic properties and selectivity 
over the structurally related LHR and TSHR. When co-incubated with FSH, Org 214444-0 
increased FSH binding to its receptor and cAMP activation in a concentration-dependent 
manner. Furthermore, in vivo, Org 214444-0 shows oral bioavailability and mimics the action 
of FSH in a follicular phase rat fertility model. Unexpectedly, a LHR PAM (Org41841) showed 
an increase in FSHR at the plasma membrane when used at sub-micromolar concentration. 
This  finding  suggests  that  Org41841  behaves  as  a  pharmacoperone  (pharmacological 
chaperone) at the FSHR. Indeed, this drug was able to rescue the expression of A189V 
FSHR (Janovick et al., 2009).
Two small molecules have been reported to compete with FSH binding on FSHR. The first 
competitive  antagonist,  suramin,  has  been  shown  to  inhibit  testosterone  production  and 
FSHR signalling  (Danesi et al., 1996, Daugherty et al., 1992). Another one has been later 
described by Arey and colleagues (Arey et al., 2002). This compound possesses the same 
antagonistic properties than suramin but with much better specificity for FSHR.
More  recently,  another  series  of  small  molecules  acting  as  ago-PAMs  were  reported 
(Nataraja  et  al.,  2015,  Sriraman  et  al.,  2014,  Yu  et  al.,  2014).  Indeed,  thiazolidinone 
derivatives  have been reported to activate  FSHR signalling  in  CHO cells  and oestradiol 
production in cultured rat granulosa cells (Sriraman et al., 2014). In addition, optimization of 
substituted  benzamides  led  to  more  FSHR-selective  molecules  relative  to  other  closely 
related GPCRs, such as LHR and TSHR with better pharmacokinetic properties  (Yu et al., 
2014).
ii) Glycosylation variants
The subunits of FSH contain several N-linked heterogeneous oligosaccharide structures that 
play a pivotal role in protein folding, oligomerization, quality control, sorting, and transport 
(Bishop et al.,  1994, Helenius and Aebi,  2001,  Ulloa-Aguirre et al.,  1999) as well  as the 
functional characteristics of the molecule itself. Carbohydrates account for nearly 20–30% of 
the hormone’s mass (Dias and Roey, 2001, Fox et al., 2001). Each primary sequence of the 
common α-subunit and FSHβ contains two N-linked oligosaccharides (positions Asn52 and 
Asn78 on FSHα and Asn7 and Asn24 in FSHβ) (Dias et al., 1998, Ulloa-Aguirre et al., 1999). 
Removal of the carbohydrate residue at position 78 on the α-subunit significantly increases 
receptor  binding affinity  of  human FSH.  Likewise,  carbohydrate  at  position  52 on the α-
subunit was found to play an essential role in signal transduction as its removal resulted in 
significant decrease in potency. Interestingly, suppression of both carbohydrates on β-subunit 
led to a better biopotency than removing both carbohydrates on α-subunit  (Bishop et al., 
1994). Moreover, β-subunit carbohydrates removal impacts on FSHβ assembly with FSHα 
resulting in loss of hormone activity and secretion in vivo (Ulloa-Aguirre et al., 2003, Wang et 
al.,  2016). Another hypoglycosylated FSH (FSH21/18) was 9- to 26-fold more active than 
fully-glycosylated FSH (tetra-glycosylated FSH24) in binding assays (Bousfield et al., 2014). 
Another  human  FSH  deglycosylated  variant,  which  possesses  only  α-subunit 
oligosaccharides is significantly more bioactive in vitro than the tetra-glycosylated form of the 
hormone  (Walton et al.,  2001, Bousfield et al.,  2007). In contrast, hyperglycosylated FSH 
showed  an  increase  in  ovulated  eggs  and  subsequent  in  vitro embryo  development 
(Trousdale et al., 2009). Collectively, these results suggest that the naturally occurring FSH 
isoforms may exhibit biased effects at the target cell level (Timossi et al., 2000).
Supporting this view, it  has been reported that partially deglycosylated eLH (eLHdg) is a 
partial agonist at the FSHR (Wehbi et al., 2010b). Interestingly, siRNA-mediated β-arrestin 
depletion revealed that eLHdg elicited β-arrestin recruitment to FSHR and activated ERK and 
rpS6 phosphorylation in a β-arrestin-dependent and Gs/cAMP-independent manner (Wehbi 
et al., 2010b).
iii) Antibodies 
In some cases, the structural constraints conveyed on the hormone by a specific monoclonal 
antibody  can  affect  the  receptor’s  activation  mechanism,  probably  by  stabilizing  distinct 
conformations and selectively triggering part of the signalling repertoire (Ulloa-Aguirre et al., 
2011).  Polyclonal  anti-peptide  antibodies  against  ovine FSHβ subunit  led  to  a significant 
enhancement of biological activity in vivo in mice (Ferasin et al., 1997). Likewise, the use of a 
monoclonal antibody against bovine FSH in the same model (i.e. snell dwarf mice) showed 
an increase in uterine weigh (Glencross et al., 1993). Equine CG binds only to the equine LH 
receptor (COMBARNOUS et al., 1984, Guillou and Combarnous, 1983), whereas it exhibits 
pronounced  FSH  activity  in  addition  to  its  LH  activity  in  species  other  than  equine 
(COMBARNOUS et al., 1978, Licht et al., 1979). Numerous studies evaluated the impact of 
eCG/anti-eCG complexes  on  gonadotropin  bioactivities.  They  showed that  anti-eCG IgG 
induced either inhibitory or hyper-stimulation on LH and FSH bioactivity (Hervé et al., 2004). 
Furthermore, Wehbi et al. discriminated the nature of these complexes on FSH signalling 
(Wehbi  et  al.,  2010a).  Despite  different  modulatory  effects  on  cAMP response  (i.e.:  two 
antibodies increase the signal vs one that decreases it), all three complexes tested displayed 
ERK  increased  in  a  β-arrestin  dependent  manner,  thereby  displaying  biased  properties 
(Wehbi et al., 2010a).
b. Receptor bias
As presented above,  thanks to clinical  studies,  a  large number  of  FSHR mutations  and 
variants have been examined over the years. Some of them have led to paradoxical results. 
The most thoroughly studied FSHR variant is the N680S, which is in linkage disequilibrium 
with the variant T307A. This variant is located at the end of the C-terminal tail of the receptor. 
This variant is found in both men and women with an allelic distribution of 60% asparagine 
and 40% serine in the normal population and 50/50 in the infertile population. In the case of  
ovarian hyperstimulation syndrome (OHSS) in ART, women who are homozygous for serine 
680  display  a  greater  severity  of  symptoms  than  heterozygotes  or  homozygotes  for 
asparagine (Daelemans et al., 2004). A study has shown kinetic differences in FSH-induced 
response at both variants: intracellular cAMP production is faster for N680 than for S680 in 
granulosa cells. Interestingly, the activation of ERK 1/2, CREB, ARGEG and STARD1 genes 
expression  as  well  as  the  production  of  oestradiol  are  differentially  modulated  by  this 
polymorphism (Casarini et al., 2014).
Another  well-studied  genetic  alteration  identified  at  the  FSHR  is  the  A189V  mutation 
(Aittomäki et al., 1995). This mutation has been classified as a loss of function because of a 
lack of plasma membrane expression. However, the phenotype in man was not consistent 
with  a  complete  lack  of  function.  A study  has  demonstrated  that  the  A189V  FSHR  is 
expressed at very low level at the plasma membrane but still functional. Indeed, when the 
wild-type receptor is expressed at a comparable level, it does not couple to the Gs/cAMP 
pathway. However, A189V and wild-type FSHR, both expressed at low levels, are able to 
induce ERK phosphorylation via the β-arrestin-dependent pathway (Tranchant et al., 2011). 
These observations  illustrate  nicely  the  concept  of  conditional  efficacy  presented earlier. 
Indeed, when receptor expression decreases, the stoichiometry of its modulating partners 
(i.e. β-arrestins in this case) changes, affecting the signalling outcome. 
Another case is the N431I mutation in the extracellular loop 1 (EL1) that has been found in a 
man with undetectable circulating FSH but normal spermatogenesis (Casas-González et al., 
2012).  This  mutation  leads  to  a  marked  decrease  in  FSH-induced  desensitization  and 
internalization. Finally, it is well established that EL2 of FSHR plays a pivotal role in various 
events downstream FSH stimulation: three naturally mutations P519T (Meduri et al., 2003), 
M512I (Uchida et al., 2013) and V514A (Desai et al., 2015) have been described in patients 
presenting  fertility  disorders.  Six  FSHR-specific  residues  in  EL2  have  been  identified  to 
impair  internalization  of  FSH–FSHR complex  and reduce FSH-induced cAMP production 
(Banerjee et al., 2015). Obviously, a lot of work remains in order to re-evaluate the structure-
activity relationships of the FSHR in order to identify possible signalling bias.
13.Conclusions
Research on FSHR is barely an emerging topic yet; many advances have been achieved 
over the last few years that open intriguing prospects in terms of pharmacological control of 
this receptor  with potential  applications in  ART and contraception.  Now that  the proof  of 
concept has been achieved that biased signalling exists for FSHR, the different classes of 
small molecule ligands identified for the FSHR, will  have to be further characterized with 
respect to their pharmacological profiles. Are they balanced or biased? The same goes for 
the  naturally  occurring  heterogeneity  in  FSH  glycan  structure  that  could  affect  FSHR 
activated  states  and  selectively  activate  intracellular  signalling  pathways.  Robust  BRET 
and/or HTRF assays are now available and should allow exploring the multiple dimensions of 
efficacy at the FSHR in a quantitative and reliable manner. Finally, molecular characterization 
of FSHR mutants and variants also needs to take into account the multiple dimension of 
FSHR efficacy. It is also very important that basic research efforts on FSHR signalling and 
trafficking continue to deliver new mechanisms and concepts, which are essential  to fuel 
innovative approaches in the control of reproduction.
Figure legends
Figure 1: Key role of FSH in reproduction. FSH is produced in the pituitary under the control 
of control neuroendocrine signals (i.e.: Kisspeptin and GnRH) secreted in the hypothalamus. 
In  the  testis,  FSH  acts  on  FSHR-expressing  Sertoli  cells  in  order  to  promote 
spermatogenesis.  In  the ovary, FSH stimulates granulosa cells  through FSHR activation, 
which in turn enhances oestrogen production and induces terminal follicular development.
Figure 2: Schematic representation of the key structural elements of the FSHR. The leucine 
rich repeats (LRR) are represented as blue arrows and numbered from 1 to 12. The pivotal 
helix from the hinge region is shown as a blue cylinder. Transmembrane helices (TM1 to 
TM7) and helix 8 are depicted as orange cylinders. Highly conserved ERW and NPxxY motifs 
as well as the sulphated Y335, which plays a key role in FSH binding affinity, are indicated in 
red. FSH- and FSH-subunits are depicted by transparent green ovoid. Extracellular (ECL1 
to 3) and Intracellular (ICL1 to 3) loops, NH2-terminal extracellular domain (ECD), hormone 
binding domain (HBD) and hinge region are delineated on the scheme.
Figure 3:  Hypothetical model of FSHR trafficking and signalling dynamics controlled by  -
arrestins.
Figure  4: Schematic  view  of  the  FSHR-induced  signalling  network  in  CellDesigner.  G-
dependent pathways are in the centre (Gαs, Gαi and Gαq in light blue) and lead to PKA and 
Akt activation. In addition to G proteins, some other proteins interact with the receptor, such 
as APPL1, which also regulate Akt activation. GRK and -arrestin-dependent action lead to 
the  degradation  or  recycling  of  the  receptor,  but  also  to  G  protein-independent  ERK 
activation. EGFR transactivation also impact PI3K and ERK activation. The major effects of 
this  network  on  transcription  (center  bottom)  and  translation  (right  bottom)  are  also 
represented.
Figure 5:  Proposed mechanism of p70S6K activation by FSH in granulosa cell and Sertoli 
cell.  (A) In  granulosa  cell,  cAMP  activates  PI3K,  Akt  and  mTOR,  which  leads  to  the 
phosphorylation of p70S6K on Thr389. Once activated, p70S6K phosphorylates rpS6, which 
participates  in  the  stabilization  of  HIF1  mRNA.  HIF1  then  stimulates  the  expression  of 
various mRNAs including VEGF, aromatase, inhibin α-subunit, LH-receptor and cyclin D2. 
(B) Activation of p70S6K by FSH in Sertoli cells involves PKA-dependent dephosphorylation 
of p70S6K autoinhibitory Thr421/Ser424 sites while the PI3-K/mTOR pathway constitutively 
phosphorylates Thr389.
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